1. Market Research
  2. > Biotechnology Market Trends
  3. > Adienne Pharma & Biotech - Product Pipeline Review - 2014

Adienne Pharma & Biotech - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 20 pages

Adienne Pharma & Biotech - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Adienne Pharma & Biotech - Product Pipeline Review - 2014’, provides an overview of the Adienne Pharma & Biotech’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Adienne Pharma & Biotech’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Adienne Pharma & Biotech including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Adienne Pharma & Biotech’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Adienne Pharma & Biotech’s pipeline products

Reasons to buy

- Evaluate Adienne Pharma & Biotech’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Adienne Pharma & Biotech in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Adienne Pharma & Biotech’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Adienne Pharma & Biotech and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Adienne Pharma & Biotech
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Adienne Pharma & Biotech and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Adienne Pharma and Biotech - Product Pipeline Review - 2014
Table of Contents
Adienne Pharma and Biotech Snapshot 4
Adienne Pharma and Biotech Overview 4
Key Information 4
Key Facts 4
Adienne Pharma and Biotech - Research and Development Overview 5
Key Therapeutic Areas 5
Adienne Pharma and Biotech - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Adienne Pharma and Biotech - Pipeline Products Glance 9
Adienne Pharma and Biotech - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Adienne Pharma and Biotech - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Adienne Pharma and Biotech - Drug Profiles 11
begelomab 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Ergidina 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Mubodina 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Adienne Pharma and Biotech - Pipeline Analysis 14
Adienne Pharma and Biotech - Pipeline Products by Target 14
Adienne Pharma and Biotech - Pipeline Products by Route of Administration 15
Adienne Pharma and Biotech - Pipeline Products by Molecule Type 16
Adienne Pharma and Biotech - Pipeline Products by Mechanism of Action 17
Adienne Pharma and Biotech - Locations And Subsidiaries 18
Head Office 18
Other Locations and Subsidiaries 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20

List of Tables

Adienne Pharma and Biotech, Key Information 4
Adienne Pharma and Biotech, Key Facts 4
Adienne Pharma and Biotech - Pipeline by Indication, 2014 6
Adienne Pharma and Biotech - Pipeline by Stage of Development, 2014 7
Adienne Pharma and Biotech - Monotherapy Products in Pipeline, 2014 8
Adienne Pharma and Biotech - Phase II, 2014 9
Adienne Pharma and Biotech - Preclinical, 2014 10
Adienne Pharma and Biotech - Pipeline by Target, 2014 14
Adienne Pharma and Biotech - Pipeline by Route of Administration, 2014 15
Adienne Pharma and Biotech - Pipeline by Molecule Type, 2014 16
Adienne Pharma and Biotech - Pipeline Products by Mechanism of Action, 2014 17
Adienne Pharma and Biotech, Subsidiaries 18

List of Figures

Adienne Pharma and Biotech - Pipeline by Top 10 Indication, 2014 6
Adienne Pharma and Biotech - Pipeline by Stage of Development, 2014 7
Adienne Pharma and Biotech - Monotherapy Products in Pipeline, 2014 8
Adienne Pharma and Biotech - Pipeline by Top 10 Target, 2014 14
Adienne Pharma and Biotech - Pipeline by Top 10 Molecule Type, 2014 16
Adienne Pharma and Biotech - Pipeline Products by Top 10 Mechanism of Action, 2014 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Telomerase ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.